论文部分内容阅读
近年来,国外癌胚抗原单克隆抗体(CEA—MCAb)的研制及其临床应用的结果,表明这一技术应用能进一步提高肿瘤病人的阳性检出率。本文报道在进行8株CEA—MCAb免疫学性状研究的基础上,建立CEA—MCAb合剂RIA及其初步临床应用,并与CEA—多克隆抗体(PCAb)RIA作对比研究。
In recent years, the development of foreign monoclonal antibodies against carcinoembryonic antigen (CEA-MCAb) and the results of its clinical application show that the application of this technology can further improve the positive detection rate of cancer patients. In this paper, based on the study of the immunological traits of 8 CEA-MCAbs, a CEA-MCAb cocktail RIA was established and its preliminary clinical application, and compared with CEA-polyclonal antibody (PCAb) RIA.